Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors
Fiona O’Neill,
Taylor-Jade Allen-Coyle,
Sandra Roche,
Justine Meiller,
Neil T. Conlon,
Niall Swan,
Robert M. Straubinger,
Justin Geoghegan,
Ninfa L. Straubinger,
Kevin Conlon,
Ray McDermott,
Finbarr O’Sullivan,
Michael Henry,
Paula Meleady,
Gerard McVey,
Robert O’Connor,
Michael Moriarty,
Martin Clynes
Affiliations
Fiona O’Neill
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Taylor-Jade Allen-Coyle
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Sandra Roche
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Justine Meiller
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Neil T. Conlon
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Niall Swan
St. Vincent’s University Hospital, D04 T6F4 Dublin, Ireland
Robert M. Straubinger
Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY 14214, USA
Justin Geoghegan
St. Vincent’s University Hospital, D04 T6F4 Dublin, Ireland
Ninfa L. Straubinger
Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY 14214, USA
Kevin Conlon
St. Vincent’s University Hospital, D04 T6F4 Dublin, Ireland
Ray McDermott
St. Vincent’s University Hospital, D04 T6F4 Dublin, Ireland
Finbarr O’Sullivan
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Michael Henry
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Paula Meleady
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Gerard McVey
St. Luke’s Hospital, Rathgar, D06 HH36 Dublin, Ireland
Robert O’Connor
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Michael Moriarty
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Martin Clynes
National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland
Herein, we describe the global comparison of miRNAs in human pancreatic cancer tumors, adjacent normal tissue, and matched patient-derived xenograft models using microarray screening. RNA was extracted from seven tumor, five adjacent normal, and eight FI PDX tumor samples and analyzed by Affymetrix GeneChip miRNA 4.0 array. A transcriptome analysis console (TAC) was used to generate comparative lists of up- and downregulated miRNAs for the comparisons, tumor vs. normal and F1 PDX vs. tumor. Particular attention was paid to miRNAs that were changed in the same direction in both comparisons. We identified the involvement in pancreatic tumor tissue of several miRNAs, including miR4534, miR3154, and miR4742, not previously highlighted as being involved in this type of cancer. Investigation in the parallel mRNA and protein lists from the same samples allowed the elimination of proteins where altered expression correlated with corresponding mRNA levels and was thus less likely to be miRNA regulated. Using the remaining differential expression protein lists for proteins predicted to be targeted for differentially expressed miRNA on our list, we were able to tentatively ascribe specific protein changes to individual miRNA. Particularly interesting target proteins for miRs 615-3p, 2467-3p, 4742-5p, 509-5p, and 605-3p were identified. Prominent among the protein targets are enzymes involved in aldehyde metabolism and membrane transport and trafficking. These results may help to uncover vulnerabilities that could enable novel approaches to treating pancreatic cancer.